Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study

BACKGROUND: Adjuvant tamoxifen therapy approximately halves the risk of recurrence in estrogen receptor-positive (ER+) breast cancer patients, but many women respond insufficiently to therapy. Expression of multi-drug resistance protein 2 (MRP2) in breast cancer may potentiate tamoxifen resistance....

Full description

Saved in:
Bibliographic Details
Published in:Acta Oncol
Main Authors: Hjorth, Cathrine F., Nielsen, Anja S., Sørensen, Henrik T., Lash, Timothy L., Damkier, Per, Hamilton-Dutoit, Stephen, Cronin-Fenton, Deirdre
Format: Artigo
Language:Inglês
Published: 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6526175/
https://ncbi.nlm.nih.gov/pubmed/30458661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/0284186X.2018.1537508
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items